Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (GB:0J2O)
LSE:0J2O
Holding GB:0J2O?
Track your performance easily
0J2O Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.22 - $65.40
Previous Close$47.88
Volume699.00
Average Volume (3M)2.04K
Market Cap
$5.97B
Enterprise Value$6.81B
Total Cash (Recent Filing)$666.31M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)15.8
Beta1.26
Next Earnings
Feb 25, 2025EPS Estimate
$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding127,227,000
10 Day Avg. Volume1,930
30 Day Avg. Volume2,036
Standard Deviation0.12
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)13.68
Price to Sales (P/S)6.31
Price to Cash Flow (P/CF)13.00
P/FCF Ratio13.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.19
Enterprise Value/Gross Profit10.70
Enterprise Value/Ebitda11.81
Forecast
1Y Price Target
$63.29Price Target Upside32.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Market Growth PotentialENHANZE technology could help capture a large portion of the U.S. infusion therapy market and drive its growth.
Regulatory ApprovalHalozyme has amassed several regulatory approvals for its Enhanze-coformulated products, giving little reason to doubt the path forward to resolve the manufacturing facility issue in a timely fashion.
Royalty Revenue GrowthConfidence remains in Halozyme's ability to achieve significant growth in royalty revenue and adjusted EBITDA, with targets of over $1 billion by 2027.
Bears Say
Acquisition ChallengesEvotec's board of directors does not appear to be open to the proposal and has hired an investment bank to prepare a defense to Halozyme's takeover bid.
Financial PerformanceHalozyme shares are down approximately 18% since the rumor emerged regarding their intention to acquire Evotec.
Intellectual Property RisksThe European Patent Office has decided to revoke another of JNJ’s co-formulation patents for Darzalex Faspro, bringing attention to a non-zero longer-term risk to HALO’s European Faspro royalties.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.99% Insiders
30.90% Mutual Funds
26.30% Other Institutional Investors
13.11% Public Companies and
Individual Investors
0J2O FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest share price was $33.22 and its highest was $65.40 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 65 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Oct 31, 2024. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $0.991 by $0.279.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $1.17.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 127,227,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.27 in its last earnings report, beating expectations of $0.991. Following the earnings report the stock price went up 12.086%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Fisher Asset Management LLC. It holds Halozyme Therapeutics’s shares valued at 19M.
---
Halozyme Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.29 (32.20% Upside)
$63.29 (32.20% Upside)
Blogger Sentiment
Bullish
GB:0J2O Sentiment 92%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.08%
12-Months-Change
Fundamentals
Return on Equity
111.83%
Trailing 12-Months
Asset Growth
11.91%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
0J2O Company Deck
---
0J2O Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting record revenue growth, successful new partnerships and approvals, and a positive outlook with increased guidance. A few challenges were noted, particularly around the MDASE platform and product sales fluctuations, but these were outweighed by the positive developments.Read More>---
0J2O Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
0J2O Stock 12 Month Forecast
Average Price Target
$63.29
▲(32.20% Upside)
Technical Analysis
Best Analysts Covering 0J2O
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+12.99%
reiterated a buy rating 4 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.99% per trade.
---